Skip to main content

Table 1 Anticancer agents and possible mechanisms for VTE [36,37]

From: Venous thromboembolism in cancer patients: an underestimated major health problem

Anticancer or supportive agent Presumed pathomechanism
Fluorinated pyrimidines (5 fluorouracil, capecitabine, tegafur-uracil, S1) Vasospasm, arterial, and venous thrombosis
Cisplatin Endothelial damage, Raynaud’s phenomenon, thrombosis (often combined with dexamethasone as an antiemetic)
L-asparaginase Alters plasma levels of procoagulants and anticoagulants (AT III, protein C, protein S)
Tamoxifen Alters plasma levels of coagulation factors
Dexamethasone Alters plasma levels of coagulation factors
Erythropoiesis-stimulating agents Alters plasma levels of coagulation factors, increased tissue factor expression
ImiDs (thalidomide, lenalidomide, etc.) Endothelial damage, altered plasma levels of F. VIII, von Willebrand factor